Related Experiment Videos
Liver disease in children with PiZZ alpha 1-antitrypsin deficiency
1Department of Pediatrics, Vanderbilt University Medical School, Nashville, Tennessee 37232.
Insights
Pediatric patients with alpha 1-antitrypsin deficiency (AATD) and PiZZ phenotype presenting with neonatal cholestatic jaundice often develop severe liver disease. Early identification and management are crucial for these AATD patients.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Genetic Liver Diseases
Background:
- Alpha 1-antitrypsin deficiency (AATD) is a genetic disorder that can lead to liver and lung disease.
- The PiZZ phenotype is the most severe form of AATD.
- Neonatal cholestatic jaundice is a potential early sign of liver disease in infants with AATD.
Purpose of the Study:
- To describe the clinical course and outcomes of pediatric patients with PiZZ AATD.
- To highlight the association between neonatal cholestatic jaundice and severe liver disease in this population.
- To compare findings with existing literature.
Main Methods:
- Retrospective review of 18 pediatric patients with PiZZ AATD.
- Analysis of clinical presentation, laboratory tests, liver biopsy findings, and long-term outcomes.
- Exclusion of other causes of neonatal jaundice.
Main Results:
- 15 of 18 patients (83%) presented with neonatal cholestatic jaundice.
- Liver biopsies showed cholestasis, giant cell hepatitis, fibrosis, or cirrhosis.
- 3 patients underwent liver transplantation; 2 died from cirrhosis complications.
- Of the remaining 10, 3 had cirrhosis and 7 had ongoing liver issues.
- 3 patients without neonatal jaundice had milder disease.
Conclusions:
- Neonatal cholestatic jaundice in PiZZ AATD patients strongly predicts severe liver disease.
- Outcomes in this cohort suggest a more aggressive disease course than reported in some recent studies.
- Close monitoring and management are essential for pediatric PiZZ AATD patients, especially those with neonatal cholestasis.
Abstract:
We present our experience with 18 pediatric patients with alpha 1-antitrypsin deficiency of the PiZZ phenotype. Fifteen patients (83%) presented with neonatal cholestatic jaundice at a mean age of 2 +/- 0.6 months (+/- S.D.). The male:female ratio was 15:3, indicating a male predominance. All metabolic, infectious and obstructive causes of jaundice were ruled out by appropriate tests in the patients with neonatal cholestasis. Liver biopsy in 14 patients with neonatal cholestasis showed a histological picture of cholestasis in all biopsies; neonatal giant cell hepatitis appeared in seven, increased fibrosis in appeared five and established liver cirrhosis appeared in two biopsies. Patients were followed for a mean of 3.7 +/- 2.4 years (+/- S.D.). Of the 15 patients with neonatal cholestasis, 3 under went liver transplantation because of decompensated liver cirrhosis at 3, 3 1/2 and 7 years. Two patients died at 4 months and 3 years from complications of liver cirrhosis. Of the remaining 10 patients, 3 had histological evidence of liver cirrhosis, and the remaining 7 patients continue to have enlarged liver and spleen with abnormal liver function tests. Of the three patients without history of neonatal cholestasis, only one had enlarged liver and spleen, and the remaining two are healthy with normal liver function tests. Our experience indicates serious liver disease is highly likely to develop in patients with PiZZ alpha 1-antitrypsin deficiency who present with neonatal cholestatic jaundice. Our experience differs from more recent reports on such patients.